ERBB2 and carcinoma: Since it is known that the presence of a PIK3CA mutation causes resistance to hormonal therapy and to classical anti-HER2 therapies, these results could help explain differences in the effectiveness of conventional and innovative treatments, including new antibody-drugs conjugates (T-DXd) in patients with PIK3CA-mutant HER2-negative and H2L carcinomas.